Pharmacovigilance – News and Features

Copernicus Therapeutics will utilize the funds for the development its non-viral gene therapy for cystic fibrosis.

The Company has initiated a safety trial using an animal model of Parkinson’s disease in primates utilizing its adult stem cell technology.

A research study identifies a common molecular trigger for the effects of toxicant exposure.

Researchers take cues from viruses to get treatment through body's protective mucus.

Tag-It™ reagents for P450-2C9 and VKORC1 to be used in a study of patients using warfarin to evaluate the potential of genetic testing.

The collaboration will allow researchs to use Affymetrix GeneChip® technology to develop applications for cancer and HIV/AIDS.

AstraZeneca uses ToxWiz to search computational models of 500 annotated pathways to determine relationships between side effects and specific proteins or pathways.

Warnex’s Medical Laboratories division will develop pharmacogenetic assays and serve as a central laboratory for several clinical studies of Schering-Plough Canada.

Two powerful tumor suppressor genes, p53 and FUS1, administered intravenously in nanoparticle formulations are capable of shrinking metastatic tumors in models of human lung cancer.

Company’s Phase III program will be the last phase of testing before it seeks full approval for Crohn’s Disease.